Investors in Erasca, Inc. (NASDAQ: ERAS) have until August 10, 2026, to seek lead plaintiff status in a federal securities class action lawsuit alleging misleading statements about its ERAS-0015 therapy and intellectual property protections. The lawsuit, captioned Cheng v. Erasca, Inc., No. 26-cv-03481, is pending in the United States District Court for the Southern District of California. Institutional investors holding positions in Erasca, Inc. during the period from January 14, 2025, through April 26, 2026, may wish to evaluate lead plaintiff opportunities. Investors who purchased securities during this period may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement.

Jonathan Lim, co-founder, Chief Executive Officer, and Chairman of the Board, and David Chacko, Chief Financial Officer and Chief Business Officer, are named as defendants under Section 20(a) of the Securities Exchange Act of 1934. The complaint alleges these officers possessed the power and authority to control the content and form of Erasca's SEC filings, press releases, and investor presentations. Both Lim and Chacko signed certifications under Sections 302 and 906 of the Sarbanes-Oxley Act for Erasca's 2024 and 2025 Annual Reports on Form 10-K, personally attesting to the accuracy of the disclosures.

The complaint alleges Erasca improperly compared its ERAS-0015 therapy to Revolution Medicines, Inc.'s RMC-6236 without a reasonable basis, touting it as a potential "best-in-class" treatment for RAS-mutant solid tumors. These comparisons were reportedly based on limited cross-study analyses rather than head-to-head clinical trials. The lawsuit further contends that Erasca failed to disclose that its preclinical data placed the company at risk of violating patent and trade secret protections held by Revolution Medicines, Inc., specifically U.S. Patent No. 12,409,225. The action asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On April 27, 2026, before the market opened, Erasca disclosed it received a letter from Revolution Medicines, Inc. alleging patent infringement and trade secret misappropriation. Revolution Medicines, Inc. also claimed Erasca had "improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures" and demanded Erasca cease making "deceptive and untrue comparative statements." Following this disclosure, Erasca's share price fell nearly 11%. After the market close on April 27, 2026, Erasca reported preliminary Phase I clinical data revealing a patient fatality classified as a Grade 3 treatment-related adverse event of pneumonitis that progressed to Grade 5. Consequently, the stock price declined more than 48% the next day. In total, shares lost $11.59 per share, a decline of approximately 53.9%, wiping out over $2.8 billion of Erasca’s market capitalization.

The lawsuit also challenges Erasca's January 23, 2026, common stock offering, which raised approximately $258.8 million. The complaint alleges the registration statement misrepresented that ERAS-0015 had "no patentability roadblocks identified to date" and claimed "no dose-limiting toxicities" despite the patient death. Erasca raised these funds through a common stock offering conducted under a shelf registration statement on Form S-3. Erasca has stated it believes the assertions are without merit and intends to contest the allegations.

Chronology of Key Events

Key Stock Movements

Pension funds, mutual funds, endowments, and asset managers that acquired ERAS shares during the Class Period face potential portfolio losses tied to allegedly artificial price inflation. Institutional holders that purchased shares in or traceable to the January 2026 offering, or on the open market during the Class Period, may have fiduciary obligations to evaluate recovery options on behalf of beneficiaries. Fiduciaries who held ERAS through the corrective disclosure period may need to document whether recovery participation was evaluated and pursued.

For plan fiduciaries governed by ERISA or analogous state pension statutes, the duty to protect plan assets may require affirmative steps when portfolio holdings suffer losses attributable to alleged securities fraud. Considerations include the destruction of more than half of Erasca's equity value in two days and the allegation that the January 2026 offering raised funds at prices artificially inflated by undisclosed patent and safety risks. Serving as lead plaintiff carries no additional financial obligation, as counsel fees are contingent and court-approved.

Investors may contact Glancy Prongay Wolke & Rotter LLP attorney Charles Linehan by calling 310-201-9150 or 888-773-9224, or via email at shareholders@glancylaw.com . Additional law firms representing investors include Levi & Korsinsky, LLP, Robbins Geller Rudman & Dowd LLP, Kahn Swick & Foti, LLC, Moore Law PLLC, SueWallSt, The Gross Law Firm, The Rosen Law Firm, P.A., The DJS Law Group, Pomerantz LLP, Bernstein Liebhard LLP, Berger Montague PC, Bragar Eagel & Squire, P.C., Kirby McInerney LLP, and Robbins LLP. Faruqi & Faruqi, LLP is also investigating claims and encourages investors to contact partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). The Rosen Law Firm, P.A. encourages investors to select qualified counsel and can be reached toll-free at 866-767-3653 or via email at case@rosenlegal.com . Robbins LLP can be reached toll-free at 800-350-6003 or via email at adumas@robbinsllp.com . Hagens Berman is also investigating claims and can be contacted at 844-916-0895 or ERAS@hbsslaw.com . Investors may also contact Kahn Swick & Foti, LLC Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email at lewis.kahn@ksfcounsel.com . The Schall Law Firm reminds investors of the class action lawsuit and encourages them to contact Brian Schall at 310-301-3335 or via email at bschall@schallfirm.com to discuss their rights. The DJS Law Group can be reached at 914-206-9742 or via email at David@djslawllp.com . Bernstein Liebhard LLP encourages investors to contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com . Bragar Eagel & Squire, P.C. partners Brandon Walker and Melissa Fortunato encourage investors to contact them by email at investigations@bespc.com or by telephone at (212) 355-4648.